Lawmakers are currently considering legislation to reauthorize FDA user fees. The FDA largely relies on user fees to operate and review innovative drugs, biologics, and devices. Not only does this legislation provide critical funding for FDA to quickly review products, but the user fee agreements also provide patients and… Read More
More than 300 organizations join forces to ask Congress to provide robust, sustained, and predictable budget increases for the NIH
Washington, D.C., September 22, 2016—… Read More
Paul Melmeyer, NORD’s Assistant Director of Public Policy, attended the FDA’s public meeting on Chagas Disease Patient-Focused Drug Development on April 28. Chagas is a rare parasitic disease (read NORD’s Rare Disease Report here) that is spread by insects. While it… Read More
NORD’s Assistant Director of Public Policy, Paul Melmeyer, authored this great piece (below) in the March 2015 issue of the NCC Collaborator, the monthly publication from the National Coordinating Center for the Genetic Service Collaboratives (NCC). NCC focuses on bringing quality genetic and newborn screening services to local communities, and… Read More
Rocky Lagno with his wife, Geralynn, Paul Melmeyer of NORD, and Carolyn Mullen of the American Association for Dental Research at the Rally for Medical Research Hill… Read More